Survival Analysis of Patients with Luminal and Non-Luminal Subtype Breast Cancer Receiving Vinorelbine Therapy at Sanglah General Hospital, Denpasar, Bali

Abstract

Introduction: Breast cancer is the most common type and lethal cancer affecting women. Meanwhile, vinorelbine is one of the chemotherapy agents used for luminal and non-luminal breast cancer. Therefore, this study aims to determine the survival difference between patients with luminal and non-luminal subtype breast cancer treated with vinorelbine.Methods: This study was a retrospective cohort. Women with breast cancer treated with vinorelbine were classified based on estrogen receptor (ER), progesteron receptor (PR), human epidermal growth factor receptor-2 (HER-2) markers, and subtypes. The subjects were followed up to chemotherapy visits with vinorelbine recorded in the medical record. The survival analysis between subtypes was analyzed by the Kaplan-Meier curve.Results: : One hundred women were obtained with a mean age of 52.36 ± 10.45 years. Based on immunohistochemistry, 60% were ER-positive, 53% were PR positive, and 57% were HER-2- positive. Based on the subtype, 67% were luminal, while 33% were non-luminal. All subjects had a mean survival duration of 155.38 days (95% CI 128.05-182.71). The stratified survival analysis showed a significant difference in survival duration based on HER-2 marker and subtype. The subjects with HER-2 positive survived longer with a mean of 203.37 days (190.72–216.02) than those with HER-2 negative with a mean of 90.10 days (65.68-114.53) (p<0.001). In addition, the subjects with the luminal subtype survived longer with a mean of 174.84 (142.72-206.94) than those with non-luminal with a mean of 90.10 (65.68-114.53) (p = 0.04).Conclusion: There was a significant difference in survival duration between women with breast cancer treated with vinorelbine chemotherapy who were HER-2 positive, HER-2 negative, and luminal and non-luminal subtypes.

Intercontinental Comparison of Immunohistochemical Subtypes Among Individuals With Breast Cancer in South-East Asia and South America: A Scoping Systematic Review and Meta-Analysis of Observational Studies

“…To exemplify the benefit of this study in issuing the imbalance of trial-patient rate, the US National Library of Medicine only recorded a single-active trial of TNBC in Indonesia; though Indonesia is placing the fourth in total population (2023 report by the Worldometer, 49.7% is female; approximately ± 135 million individuals) [6,61]. We also estimated that 17.8% of the BC diagnosis in Indonesia is triple-negative on IHC [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]. Supported by the GLOBOCAN 2020 country-specific report, at least there was 65,858 total BC cases (in which 11,000 -12,000 of the patients are estimated to be TNBC on testing) [1].…”